vimarsana.com
Home
Live Updates
MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability -January 30, 2024 at 02:52 am EST : comparemela.com
MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability -January 30, 2024 at 02:52 am EST
EQS-News: MorphoSys AG
/ Key word: Forecast
MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces...
Related Keywords
United States ,
Boston ,
Massachusetts ,
Germany ,
Canada ,
Planegg ,
Bayern ,
Julia Neugebauer ,
Thomas Biegi ,
Jean Paul Kress ,
Eamonn Nolan ,
Drug Administration ,
Xencor Inc ,
European Medicines Agency ,
Corporate Affairs ,
Constellation Pharmaceuticals Inc ,
Corporate Communications Investor Relations ,
Nasdaq ,
Linkedin ,
Exchange Commission ,
Twitter ,
Lymphoma Society ,
Sys Reports Preliminary ,
Product Sales ,
Gross Margin ,
Reduces Financial ,
Chief Executive Officer ,
Morphosy Phase ,
Antibody Dependent Cell Mediated Cytotoxicity ,
Antibody Dependent Cellular Phagocytosis ,
Prescribing Information ,
Morphosy Annual Report ,
Vice President ,
Global Investor ,
Corporate Communications ,
Markets ,
comparemela.com © 2020. All Rights Reserved.